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AbsTrACT
background Four genetic causes of isolated congenital 
central hypothyroidism (ceH) have been identified, 
but many cases remain unexplained. We hypothesised 
the existence of other genetic causes of ceH with a 
Mendelian inheritance pattern.
Methods We performed exome sequencing in two 
families with unexplained isolated ceH and subsequently 
Sanger sequenced unrelated idiopathic ceH cases. We 
performed clinical and biochemical characterisation of 
the probands and carriers identified by family screening. 
We investigated IRS4 mrna expression in human 
hypothalamus and pituitary tissue, and measured serum 
thyroid hormones and Trh and Tshb mrna expression in 
hypothalamus and pituitary tissue of irs4 knockout mice.
results We found mutations in the insulin receptor 
substrate 4 (IRS4) gene in two pairs of brothers with ceH 
(one nonsense, one frameshift). Sequencing of irS4 in 
12 unrelated ceH cases negative for variants in known 
genes yielded three frameshift mutations (two novel) 
in three patients and one male sibling. all male carriers 
(n=8) had ceH with plasma free thyroxine concentrations 
below the reference interval. Mri of the hypothalamus 
and pituitary showed no structural abnormalities (n=12). 
24-hour thyroid-stimulating hormone (tSH) secretion 
profiles in two adult male patients showed decreased 
basal, pulsatile and total tSH secretion. IRS4 mrna 
was expressed in human hypothalamic nuclei, including 
the paraventricular nucleus, and in the pituitary gland. 
Female knockout mice showed decreased pituitary Tshb 
mrna levels but had unchanged serum thyroid hormone 
concentrations.
Conclusions Mutations in IRS4 are associated with 
isolated ceH in male carriers. as irS4 is involved in leptin 
signalling, the phenotype may be related to disrupted 
leptin signalling.
InTroduCTIon
Central hypothyroidism (CeH) is characterised 
by thyroid hormone deficiency due to insuffi-
cient production of thyroid-stimulating hormone 
(TSH).1 Congenital CeH is often part of multiple 
pituitary hormone deficiency, but isolated TSH 
deficiency occurs in 20%–25% of cases. Known 
genetic causes of congenital isolated CeH include 
mutations in TSHB, TRHR, IGSF1 and TBL1X.2–5 
However, many cases remain unsolved.
In this study, we used ‘whole’ exome sequencing 
(WES) to identify the genetic cause of isolated CeH 
in two unrelated families. We identified mutations in 
insulin receptor substrate 4 (IRS4) in both families. 
Sanger sequencing in other cases of CeH identified 
IRS4 mutations in three families. The IRS family 
acts as interface between tyrosine kinase receptors, 
including the insulin, leptin and insulin-like growth 
factor 1 (IGF-1) receptors, and multiple intracel-
lular signalling pathways.6 Although the precise 
function of IRS4 is unclear, its discrete expression 
in rat hypothalamic nuclei suggests a specialised 
neuroendocrine function(s).7
MeThods
Patient acquisition
In contrast to TSH-based neonatal congenital 
hypothyroidism (CH) screening programmes, the 
Dutch thyroxine (T4)+TSH+T4 binding glob-
ulin (TBG)-based screening effectively detects 
primary CH and congenital CeH.8 9 Many of these 
children are treated by the Department of Paedi-
atric Endocrinology of the Academic Medical 
Center, University of Amsterdam.10 We studied 
two pairs of brothers: 18-year-old A.III.4 and 
his 14-year-old brother A.III.5 (figure 1A), and 
12-year-old B.III.4 and his 22-year-old maternal 
half-brother B.III.3 (figure 1B). The first three 
were detected by neonatal screening and were diag-
nosed with congenital CeH at the age of 2 weeks. 
B.III.3, who was born before optimisation of the 
Dutch neonatal screening programme for CeH, 
had normal screening results and was diagnosed 
after presenting with short stature and delayed 
tooth eruption at age 12 years (table 1). In all four, 
the diagnosis CeH was supported by thyrotro-
pin-releasing hormone (TRH) stimulation testing 
(online supplemental table 1), while additional 
endocrine testing demonstrated normal func-
tioning of the other hypothalamic–pituitary axes. 
Levothyroxine (LT4) treatment was started in all. 
While A.III.5, B.III.3 and B.III.4 have grown and 
developed normally, A.III.4 had a delayed pubertal 
growth. Testosterone-primed growth hormone 
(GH) stimulation tests were normal. With sponta-
neous progression of puberty, his growth improved, 
resulting in a normal adult height (online supple-
mental table 2). All four patients tested negative 
for mutations in TSHB, TRHR, IGSF1, and TBL1X.
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Figure 1 Pedigrees of five families with IRS4 mutations. Probands are indicated by an arrow; small horizontal lines indicate that Dna sequence analysis 
was performed. Black filled symbols represent mutation carrying individuals. (a) Pedigree of family a, (B) family B, (c) family c, (D) family D and (e) family e.
Figure 2 Schematic of irS4 and the positions of the mutations. PH, pleckstrin homology domain; PtB, phosphotyrosine-binding domain; Pi3K, 
phosphoinositide 3-kinase (region containing multiple Pi3K binding motifs); grb2, growth factor receptor-bound protein-2  (grb2 binding site). Mutations 
are indicated with black bars.
Genetic analyses
Genomic DNA isolation was performed as described previously.4 
WES and variant calling were conducted using BWA-MEM 
(0.7.5), GenomeAnalysisTK-2.8–1-g932cd3a, Cartagenia 3.0. 
and the SeqCap EZ Human Exome Library v3.0 kit (NimbleGen; 
Roche, Madison, Wisconsin, USA) on a HiSeq2000 (Illumina, 
San Diego, California, USA). Variants were filtered and analysed 
as described previously.5 Candidate variants were confirmed by 
Sanger sequencing. WES was performed in the four probands; 
Sanger sequencing was performed in all their available first-de-
gree and second-degree relatives and in other patients with idio-
pathic isolated CeH. Written informed consent was obtained in 
all cases.
Phenotyping
Clinical studies
Mutation carriers underwent assessment of growth and devel-
opment, biochemical evaluation of hypothalamus–pituitary axes 
and glucose homeostasis, thyroid ultrasound and pituitary MRI. 
Two patients (A.III.4 and B.III.3) underwent 24-hour blood 
sampling to assess TSH secretion, as described earlier.11 Testicular 
ultrasound was performed in all male mutation carriers aged 12 
years or older. Mutation carriers additionally underwent hearing 
assessment by pure tone audiometry (PTA) or otoacoustic emis-
sion testing. PTA was performed in a soundproof booth, using 
a manual audiometer (Madsen Electronics, Taastrup, Denmark) 
with TDH-39 headphones, calibrated according to ISO-389–1, 
with adequate masking.12
Endocrine measurements
Plasma free T4 (FT4) and prolactin concentrations were 
measured by fluoroimmunoassay using the Delfia 1232 Fluo-
rometer (Wallac, Turku, Finland), while total T4, triiodothy-
ronine (T3) and reverse T3 (rT3) were measured by an inhouse 
radioimmunoassay (RIA).13 Plasma TSH, luteinizing hormone 
(LH), follicle-stimulating hormone (FSH) and 17β-oestradiol 
were measured by electrochemiluminescence assay using the 
Roche cobas e602 (Roche Diagnostics, Mannheim, Germany). 
Plasma TBG and serum thyroglobulin were measured by a 
RIA (BRAHMS, Thermo-Scientific Hennigsdorf, Germany).
Plasma testosterone was measured by an inhouse method using 
the Acquity ultra-performance liquid chromatography-tandem 
mass spectrometry system (Waters, Milford, Massachusetts, 
USA). Serum sex hormone-binding globulin (SHBG) was 
measured with immunoluminometric assay (ILMA) using the 
Architect iSR2000 (Abbott Laboratories, Diagnostics Division, 
Illinois, USA). Serum IGF-1 and GH was measured with elec-
trochemiluminiscence assay using the Liaison (Diasorin, S.P.A., 
Saluggia, Italy). Plasma insulin, insulin growth factor binding 
protein 3, adrenocorticotropic hormone and cortisol were 
measured by ILMA using the Immulite 2000 (Siemens Medical 
Solutions, Camberley, UK).
Plasma total cholesterol was measured with enzymatic colori-
metric assay using the Roche cobas c502, while triglycerides and 
glucose were measured with enzymatic colorimetric assay using 
the Roche cobas c702 (both from Roche Diagnostics). Plasma 
leptin concentrations were measured with a RIA from Millipore 
(Billerica, Massachusetts, USA).
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mrnA expression in human tissue samples
Three unfixed, frozen (−80°C) human hypothalami and pitu-
itaries were obtained from the Netherlands Brain Bank (NBB) 
and used for mRNA expression. Permission for brain autopsy 
and for the use of human brain material and clinical informa-
tion for research purposes had been obtained according to the 
protocols of the NBB. Serial coronal 50 µm sections were cut 
from unfixed frozen hypothalami on a cryostat. We collected 
all consecutive sections from the level of the lamina terminalis 
to the mammillary bodies as previously described.14 RNA was 
extracted from the supraoptic, paraventricular and infundibular 
nuclei, and lateral hypothalamic area and from the homogenised 
pituitaries using TriReagent (Sigma) per the manufacturer’s 
instructions, followed by DNase treatment (Qiagen GmbH, 
Germany). cDNA was synthesised with an Applied Biosystem 
Kit. From every sample, an RT reaction was performed in order 
to check for genomic DNA contamination.
PCr
Primers were designed to amplify IRS4 transcript (NM_003604.2, 
F:5′-CCCCCGGAGAGAGAAGAT-3′, R: 5′- ACTG TAGA CTGT 
AGCG CATCG- 3′, product size 171 bp, annealing temperature 
65°C). Real-time PCR was performed using the Lightcycler480 
(Roche Molecular Biochemicals, Mannheim, Germany) and 
SensiFAST SYBR No-ROX Kit (Bioline, London, UK). Melting 
curve analysis was performed, and product size was determined 
by DNA gel analysis. All samples contained mRNA as checked 
by hypoxanthine phosphoribosyl transferase (HPRT) expression 
(a housekeeping gene).14
Mouse studies
Irs4 knockout (KO) (hemizygous males and homozygous females) 
and wild-type (WT) (B6129SF2/J) mice (n=6 per group) were 
bred at Jackson Laboratories (Jax, Bar Harbour, Maine, USA). 
Serum, brain and pituitaries from mice that are 6–8 weeks 
old were collected at the Jax facility, frozen and shipped on dry 
ice. We measured serum thyroid hormones, and Trh and Tshb 
mRNA expression in brain tissue.
Serum thyroid hormone concentrations
Serum TSH levels were measured using a mouse Pituitary 
Magnetic Bead panel for TSH (MILLIPLEX), following the 
instructions of the manufacturer (Merck-Millipore, Darmstadt, 
Germany) and read on a BioPlex (BioRad). Total T4 and T3 
were measured by an inhouse RIA.13 In order to prevent inter-
assay variation, all samples of one experiment were measured 
within the same assay (intra-assay variation: TSH: 9%–12%, T3: 
3.6% and T4: 6.6%).
RNA isolation and qPCR
Total RNA from the pituitary was isolated using TriReagent 
(Ambion) and the Nucleospin RNA kit (Macherey-Nagel, 
Duren, Germany). RNA concentrations were determined using 
the Denovix spectrophotometer (Denovix, Wilmington, Dela-
ware USA). The cDNA synthesis was carried out using equal 
RNA input and the first strand AMV cDNA synthesis kit (Roche 
Molecular Systems, Pleasanton, California, USA). Quantitative 
PCR was performed using the Lightcycler 480 apparatus and 
the SensiFAST SYBR No-ROX Kit (Bioline) and according to 
the Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) guidelines. Quantification was 
performed using the LinReg software. Samples with a mean 
deviation of more than 5% of the mean efficiency value of the 
assay were excluded. Calculated values were normalised by the 
geometric mean of three reference gene values (HPRT, EF1a1 
and cyclophilin), which were selected to be the most stable 
among different groups. The primers used were previously 
described.15 16
In situ hybridisation
Twenty-micrometre brain sections were cut on a cryostat (Leica). 
Riboprobe synthesis and in situ hybridisation for Trh mRNA 
were carried out as reported before.15
statistics
Student’s t-test was used to compare results of patients and 
controls (SPSS V.23 for Windows). P value of <0.05 was consid-
ered significant. For the mouse studies, effects of sex and geno-
type were assessed by two-way analysis of variance followed 
by a post hoc test (Tukey’s or Sidak’s) with GraphPad software 
(GraphPad Prism 7, La Jolla, California, USA).
resuLTs
WES revealed nonsense or frameshift mutations in X-linked IRS4 
(transcript accession number NM_003604.2) in the two pairs of 
brothers. Sanger sequencing in 12 other unrelated patients with 
congenital isolated CeH revealed three (two novel) frameshift 
mutations in IRS4 in three patients (table 1, figures 1C–E and 2): 
two 5-year-old boys (C.III.2 and E.III.4), and a 10-month-old 
boy (D.III.6). All three had been detected by neonatal screening 
and were treated with LT4. Off-treatment re-evaluation of the 
hypothalamus–pituitary–thyroid (HPT) axis in patients C.III.2 
and E.III.4 at age 3 years confirmed the initial CeH diagnosis in 
C.III.2, and LT4 was restarted; although E.III.4 had repeatedly 
too-low neonatal FT4 concentrations and a blunted TRH test in 
the neonatal period, re-evaluation showed FT4 concentrations 
around the lower limit of the reference interval (10.3 pmol/L). 
Because of clinical signs of hypothyroidism, he was also restarted 
on LT4. All three boys grew and developed normally. All 
probands tested negative for mutations in TSHB, TRHR, IGSF1 
and TBL1X. The IRS4 mutations were found in 14 relatives (one 
male; E.III.5). Ten individuals were included in the study, while 
four women (two adults, two children) declined participation. 
Three-year-old E.III.5 was diagnosed with CeH during endo-
crine evaluation for the present study and subsequently started 
on LT4. In retrospect, he had a low neonatal screening total T4 
concentration with low TBG (129 nmol/L; neonatal reference 
interval: 160–750 nmol/L).17
Families B and E had the same c.1772dupG mutation (table 1), 
which was found with a minor allele frequency of 0.47% in 
the Exome Aggregation Consortium (ExAC, http:// exac. broa-
dinstitute. org; none hemizygotes), but did not occur in GoNL 
(http://www. nlgenome. nl/), Scripps Wellderly (https:// genomics. 
scripps. edu/ browser/) or in 300 house reference samples. The 
other three mutations (A: c.643G>T; C: c.3161_3165del; D: 
c.1587_1588insT) were novel.
Clinical characteristics
Endocrine and anthropometric findings
All male IRS4 mutation carriers (n=8) showed biochemical 
CeH, with FT4 concentrations between 72% and 97.5% of 
the lower limit of the reference interval (table 1, figure 3A,B). 
Female heterozygous carriers (n=8) had FT4 concentrations 
within the lower half of the reference interval. One female 
carrier had a slightly elevated T3 concentration (A.II.6), while 
all others had T3 concentrations within the reference interval. 
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Figure 3 Plasma Ft4 and tSH concentrations. (a) plasma Ft4 and (B) tSH concentrations in untreated condition. neonates: neonates with IRS4 
mutations; adults/children: adults and children with IRS4 mutations (black filled symbols: males; white filled symbols: females); controls: adult controls. 
the grey shaded areas denote the reference intervals. reference intervals for Ft4: 10–23 pmol/l (adults and children) and 12–30 pmol/l (neonates), and 
tSH: 0.5–5 mU/l (adults and children) and 1.7–7.9 mU/l (neonates). the adult controls (n=136) were recruited in earlier studies for the express purpose 
of establishing reference intervals and were all healthy subjects, not suspected to have endocrine disorders.5 (c) basal, pulsatile and total tSH secretion of 
individuals with IRS4 mutations (blue triangles) and healthy controls (box plots). (D) the 24-hour secretion profiles of tSH in individuals with IRS4 mutations 
(black lines) and healthy controls (coloured lines). Ft4, free thyroxine; tSH, thyroid-stimulating hormone.
T3/T4 ratios were elevated compared with those of euthyroid 
adult controls.18 TRH testing (performed before LT4 treatment) 
showed a blunted peak TSH in six of seven males, compatible 
with CeH (online supplemental table 1).
Mean (fasted) IGF-1 plasma concentration was +1.1 SD score. 
Serum leptin concentrations were within the age-specific 
and sex-specific reference intervals in 12 carriers and above 
the reference interval in four carriers (two infants, two adult 
females). Height, body mass index (BMI) and biochemical eval-
uation of other hypothalamus–pituitary axes were unremarkable 
(online supplemental table 3).
Oral glucose tolerance tests (OGTT) in carriers aged 6 years 
or older (online supplemental table 4) demonstrated normal 
glucose concentrations, both fasting and 2 hours after inges-
tion of a glucose load. Homeostatic model assessment of insulin 
resistance (HOMA-IR) showed insulin resistance in 3 of 15 
individuals (online supplemental table 5). Data on low-density 
lipoprotein, total cholesterol concentrations and sex hormone-
binding globulin concentrations are given in online supplemental 
tables 3 and 6.
Twenty-four-hour TSH secretion profiles in 2 adult male 
patients and 11 healthy controls (online supplemental table 7) 
showed markedly decreased basal, pulsatile and total secretion 
of TSH in patients, even though their FT4 concentrations were 
significantly lower (figure 3C,D).
Imaging
Pituitary MRI in 12 carriers showed normal morphology of 
the hypothalamus and the pituitary. Ultrasonography showed 
thyroid volumes below the 2.5th percentile in two adult males 
(both treated with LT4), and well below the 50th percentile in 
five boys (three treated with LT4) (table 1).19 Thyroid volumes 
were below the 50th percentile in seven of eight adult women 
(none treated with LT4).20 In a 1-year-old boy (treated with 
LT4) and a 6-month-old girl (not treated with LT4), thyroid 
volumes could not be calculated reliably because of their age. 
Testicular volume was normal in the four adolescent and adult 
men.21
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Audiometry
Three of 15 carriers (all adults, one male) had hearing thresholds 
poorer than the age-specific reference interval without clinical 
manifestations.22
Tissue studies
IRS4 mRNA was expressed in the several human hypothalamic 
nuclei, including the paraventricular nucleus, and the pituitary 
gland (online supplemental figure 1).
Mouse studies
Trh mRNA expression in the paraventricular nucleus of the hypo-
thalamus was assessed with in situ hybridisation. No significant 
differences in hybridisation signal were observed between WT 
and KO mice, or between male and female mice (online supple-
mental figure 2A). Tshb mRNA in the pituitary was markedly 
decreased (p=0.04) in KO females compared with WT females, 
but no differences were observed in males (online supplemental 
figure 2B). This difference was not reflected in serum TSH, T4 
or T3 concentrations. In both the WT and KO groups, females 
had lower serum TSH levels than males. Serum T4, but not T3, 
was higher in WT females compared with males. No differences 
in either serum TSH, T4 or T3 were observed between KO mice 
compared with WT mice (online supplemental figure 2C–E).
dIsCussIon
In this study, we identified four mutations (one nonsense and 
three frameshift) in IRS4 in seven male patients with CeH from 
five families. Further investigations yielded mutations in 14 
relatives, including one male who was subsequently also diag-
nosed with CeH. Male carriers met the biochemical criteria of 
CeH, and FT4 concentrations of all female carriers were in the 
lower half of the reference interval (figure 3). Six of seven male 
carriers had blunted TRH test results. All carriers had relatively 
low thyroid volumes, in keeping with relative TSH deficiency. 
While most carriers had T3 concentrations within the age-ap-
propriate reference intervals, adult T3/T4 ratios were slightly 
higher compared with euthyroid subjects.18 Although T3/T4 
ratios have not been reported in untreated patients with CeH, 
untreated TBL1X mutation carriers also had T3 concentra-
tions within reference interval combined with low-normal T4 
concentrations, suggesting a slightly increased ratio.5 These find-
ings may help distinguish CeH from the non-thyroidal illness 
syndrome, which is associated with reduced serum T3 concen-
trations,23 and thus decreased T3/T4 ratios. All male carriers 
had cholesterol and SHBG levels within the reference interval, 
although this was measured during treatment with LT4, while 
three female mutation carriers had SHBG concentrations below 
the reference interval. Two of these women had elevated total 
cholesterol levels. Since low levels of SHBG and elevated lipid 
levels are associated with hypothyroidism,24 25 this may point 
to a certain degree of hypothyroidism at the target tissue level, 
although the number of observations is too small, and the varia-
tion in the population is too large to draw any firm conclusions 
at this stage.
Mutations in IRS4 have not been associated with CeH before. 
A missense mutation has been described in a female with para-
noid schizophrenia, but thyroid function was not reported in this 
patient.26 In addition, IRS4 mutations have been associated with 
a higher BMI in patients with schizophrenia,27 and IRS4 was 
found to be associated with body size in dogs.28 Only three loss-
of-function mutations in IRS4 are reported in the ExAC database, 
none of which were homozygous or hemizygous. Although two 
other genes associated with isolated CeH, TBL1X and IGSF1, 
are also located on the X-chromosome, they are distant from 
IRS4, with IRS4 located on Xq22.3, TBL1X on Xp22.3-p22.2 
and IGSF1 on Xq26.1.
IRS4 is located on the X-chromosome and encodes a 1257 
amino acid protein, which contains a pleckstrin homology (PH) 
domain and a phosphotyrosine-binding (PTB) domain in the 
N-terminal region, followed by multiple tyrosine and serine 
phosphorylation sites in the C-terminal tail.29 IRS4 is part of the 
IRS family, which contains six members (IRS1–6). All proteins 
contain PTB domains and multiple glycosylation sites to induce 
a cascade in hormone signalling pathways.29 The best character-
ised are IRS1 and IRS2, which are involved in insulin signalling 
and of which knockdown results in marked dysregulation of 
growth and metabolic homeostasis.30 31 The function of IRS3-6 
is still uncertain but thought to be highly specific due to their 
restricted tissue distribution.32 IRS3 and IRS4 were found to 
influence actions of IRS1 and IRS2.33 Although IRS1 and IRS2 
were found to be non-redundant, function interchangeability 
was found between IRS1 and IRS3. The functional overlap 
between other family members is still under investigation.32
The IRS4 protein binds to and is activated by the intracellular 
domain of tyrosine kinase receptors, most notably the insulin, 
IGF-1 and leptin receptors (IR, IGF1R and LEPR).6 IRS4 mRNA 
is expressed in the pituitary gland and hypothalamus,7 skeletal 
muscle, heart, kidney and liver of rats.34 In human tissue, RNA 
expression was detected in hypothalamus, pituitary, thyroid and 
ovary tissue (http://www. proteinatlas. org/ ENSG00000133124- 
IRS4/ tissue; accessed 6 May 2017). In the present study, we 
confirmed IRS4 mRNA expression in the human pituitary gland 
and found expression in a number of hypothalamic nuclei, 
including the paraventricular nucleus. Although we did not 
measure IRS4 protein expression, marked RNA expression 
suggests the presence of protein in those tissues.
IRS4 KO mice were reported to exhibit mild metabolic differ-
ences compared with WT mice. Particularly males were slightly 
smaller, exhibited lower blood glucose levels in fasted and fed 
states and had an impaired OGTT. Additionally, KO pairs repro-
duced less well, attributed to decreased fertility of females. Their 
thyroid function was not reported.35
In this study, we found that Irs4 KO mice did not have reduced 
serum TSH or thyroid hormone concentrations, despite clearly 
decreased Tshb mRNA expression in the pituitaries of KO 
females. In addition, we found no significant effect of IRS4 
absence on Trh expression in the hypothalamus. The finding that 
Tshb mRNA expression was decreased only in female Irs4 KO 
mice and that female KO and WT mice had somewhat lower 
TSH concentrations than male KO and WT mice may suggest 
the presence of sexual dimorphism in the HPT axis. Although 
other characteristics of Irs4 deficiency seem more pronounced in 
males,35 this may suggest that female mice require Irs4 for suffi-
cient Tshb transcription, while males do not. The mouse data 
seem to contradict the human findings, suggesting that KO mice 
may not be an optimal model. IRS4 expression may vary between 
species and have different contributions to the regulation of 
the HPT-axis. A similar situation has been reported for other 
genes; one example is the mouse model for IGSF1 deficiency, 
which does not show the decreased serum total thyroid hormone 
concentrations seen in human patients.36 This also holds true for 
MCT8, a TH transporter; patients with a mutation in MCT8 
have a serious neurologic phenotype (Allan–Herndon–Dudley 
syndrome), while MCT8 KO mice behave normally.37
Although impaired glucose tolerance was reported in Irs4-null 
mice,35 in this study, IRS4 mutation carriers did not show signs 
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of glucose intolerance. All patients with IRS4 mutations had a 
normal height and weight. One female carrier underwent fertility 
treatment for fallopian tube obstruction. Due to the association 
of IRS4 with IR, IGF1R and LEPR, we considered the possibility 
that mutations in IRS4 impair the signalling capability of these 
receptors. However, patients in this study had no abnormalities 
in either OGTT or HOMA, suggesting a normal insulin sensi-
tivity, nor did they exhibit growth failure. Furthermore, thyroid 
function in patients with INSR or IGF1R mutations has been 
reported as being normal.38 39 These findings make a role for 
IR and IGF1R in the pathogenesis of CeH in patients with IRS4 
mutations unlikely.
The combination of these findings emphasises the complexity 
of the central regulation the HPT axis and indicates that further 
research is necessary before a (putative) mechanism explaining 
the decreased plasma T4 concentrations in patients harbouring 
a mutation in IRS4 can be proposed. For instance, testing of the 
HPT axis in a more dynamic way in mice and other species with 
mutations more similar to those in the human patients may offer 
more insight.
Hypothalamic leptin signalling is closely associated with 
thyroid function. During starvation, decreasing leptin concen-
trations lead to reduced TRH expression in the paraventric-
ular nucleus, contributing to persistently low plasma TSH and 
thyroid hormone concentrations. This response to fasting may 
function to conserve energy.40 Leptin acts on the HPT axis 
directly through receptors on hypophysiotropic TRH neurons 
that upregulate proTRH production and conversion to TRH40 
and indirectly through pro-opiomelanocortin and neuropeptide 
Y/agouti-related peptide expressing neurons in the hypothalamic 
arcuate nucleus that project to TRH neurons.41 In healthy men 
who were fasted for 72 hours, 24-hour TSH secretion studies 
showed normal baseline concentrations but marked suppression 
of TSH secretion and loss of typical pulsatility characteristics. 
The fasting-induced decrease in TSH pulsatility was restored by 
leptin administration.42 Additionally, 56-hour fasting in healthy 
men and women was shown to decrease TSH responses to 
TRH by 43% below baseline responses.43 In the present study, 
IRS4-mutated patients showed remarkably similar TSH baseline 
concentrations, 24-hour TSH secretion patterns and TRH test 
results. These data may suggest that the central downregula-
tion of the HPT axis in patients with IRS4 mutations is medi-
ated by subtle hypothalamic LEPR dysfunction. Leptin-deficient 
patients have a highly heterogeneous phenotype, with case-se-
ries describing subclinical hypothyroidism with increased TSH 
and normal FT4 levels,44 normal thyroid function45 and normal 
TSH concentrations combined with relatively low FT4 concen-
trations, which increased after treatment with r-metHuLeptin.46 
TRH tests in these patients were normal and exaggerated in a 
subclinical hypothyroid patient.44 Interestingly, 24-hour TSH 
secretion studies in leptin-deficient patients found suppression of 
TSH secretion46 and variable loss of organisation of TSH pulsa-
tility which, in one study, was strongly correlated to the 24-hour 
leptin secretion.47 Leptin-resistant patients were described 
to have either normal thyroid function, or low levels of FT4 
combined with normal levels of TSH, similar to patients with 
mutations in IRS4. However, these patients showed an exagger-
ated and sustained TSH response to TRH, while IRS4 mutation 
patients had a blunted response to TRH.48 Whether IRS4-mu-
tated patients may have LEPR dysfunction is highly speculative 
at this time, and the mechanism behind the development of CeH 
in these individuals requires further investigation.
An interesting topic for further investigation is TSH bioac-
tivity in patients with IRS4 mutations. Decreased TSH bioactivity 
has been described in several Mendelian causes of isolated CeH, 
such as mutations in TSHB and TRHR.1 Whether this is also the 
case in patients with IRS4 mutations remains to be studied.
In conclusion, we identified IRS4 mutations in patients with 
congenital isolated CeH. Although Irs4 KO mice did not display 
CeH, the human data suggest that IRS4 represents a novel 
genetic cause of isolated CeH.
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